NCT01623349 2021-02-10Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerDana-Farber Cancer InstitutePhase 1 Completed118 enrolled